Advertisement
Singapore markets closed

  • Straits Times Index

    3,280.10
    -7.65 (-0.23%)
     

  • Nikkei

    37,934.76
    +306.28 (+0.81%)
     

  • Hang Seng

    17,651.15
    +366.61 (+2.12%)
     

  • FTSE 100

    8,117.77
    +38.91 (+0.48%)
     

  • Bitcoin USD

    64,220.45
    +505.42 (+0.79%)
     

  • CMC Crypto 200

    1,383.71
    -12.82 (-0.92%)
     

  • S&P 500

    5,048.42
    -23.21 (-0.46%)
     

  • Dow

    38,085.80
    -375.12 (-0.98%)
     

  • Nasdaq

    15,611.76
    -100.99 (-0.64%)
     

  • Gold

    2,359.60
    +17.10 (+0.73%)
     

  • Crude Oil

    84.08
    +0.51 (+0.61%)
     

  • 10-Yr Bond

    4.7060
    +0.0540 (+1.16%)
     

  • FTSE Bursa Malaysia

    1,575.16
    +5.91 (+0.38%)
     

  • Jakarta Composite Index

    7,036.08
    -119.22 (-1.67%)
     

  • PSE Index

    6,628.75
    +53.87 (+0.82%)
     

My 3 Favorite Under-the-Radar Healthcare Stocks for 2022

Josh Kohn-Lindquist, The Motley Fool
·5-min read
My 3 Favorite Under-the-Radar Healthcare Stocks for 2022

Looking for investment opportunities in the healthcare sector, and particularly in the biotechnology industry, can be overwhelming if you're not intimately familiar with the space. Here are three companies that operate surprisingly diverse operations -- either through drug pipeline variety, customer diversification, or differentiated product verticals -- offering a safety net, as well as prospects for growth, to their shareholders as a result. Led by its mission "to help people access, understand, and benefit from the human genome," 23andMe Holding (NASDAQ: ME) has quietly identified over 40 therapeutic programs from its treasure trove of genetic data.

Continue reading